HUM vs. CNC, MOH, CI, ELV, IDXX, ALC, IQV, TAK, COR, and HLN
Should you be buying Humana stock or one of its competitors? The main competitors of Humana include Centene (CNC), Molina Healthcare (MOH), The Cigna Group (CI), Elevance Health (ELV), IDEXX Laboratories (IDXX), Alcon (ALC), IQVIA (IQV), Takeda Pharmaceutical (TAK), Cencora (COR), and Haleon (HLN). These companies are all part of the "medical" sector.
Centene (NYSE:CNC) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation.
Humana has a net margin of 1.82% compared to Humana's net margin of 1.76%. Centene's return on equity of 17.76% beat Humana's return on equity.
93.6% of Centene shares are owned by institutional investors. Comparatively, 92.4% of Humana shares are owned by institutional investors. 0.3% of Centene shares are owned by insiders. Comparatively, 0.3% of Humana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Centene has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
In the previous week, Centene had 12 more articles in the media than Humana. MarketBeat recorded 20 mentions for Centene and 8 mentions for Humana. Centene's average media sentiment score of 1.07 beat Humana's score of 0.81 indicating that Humana is being referred to more favorably in the news media.
Centene received 129 more outperform votes than Humana when rated by MarketBeat users. Likewise, 73.25% of users gave Centene an outperform vote while only 64.10% of users gave Humana an outperform vote.
Centene has higher revenue and earnings than Humana. Centene is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.
Centene currently has a consensus price target of $85.23, suggesting a potential upside of 15.49%. Humana has a consensus price target of $426.39, suggesting a potential upside of 22.17%. Given Centene's higher possible upside, analysts plainly believe Humana is more favorable than Centene.
Summary
Humana beats Centene on 10 of the 17 factors compared between the two stocks.
Get Humana News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
